ICP Pharmacist Clinical Leads
Role description
Numbering 17 in total each Pharmacist Clinical Lead will agree a workplan
and objectives with the Integrated Care Regional GP Clinical Lead and Local
Pharmacy Co-ordinator and regularly report to them on progress against
objectives.
OBJECTIVES




To ensure that patients and clients within the ICP area receive the
highest standard of care possible within the available resources.
To ensure that services provided are safe, evidence based and as cost
effective and efficient as possible in meeting patient & client need
To work with Integrated Care to ensure that emerging needs of the ICP
community are identified, prioritised and addressed effectively with
particular focus on the priorities of frail elderly, respiratory conditions,
diabetes and end of life care in these conditions (FREDS).
To engage and work with local service providers across primary and
secondary care in co-ordinating the service response to the strategic
commissioning of pharmaceutical services as set out by Integrated
Care.
Clinical engagement
o Internal
The Pharmacist Clinical Lead will liaise with pharmacy and GMS
contractors to review pharmacy and medicines management
activities to identify areas of service improvement and review
initiatives as they are applied with particular regard to Risk
Stratification, Information Sharing, Care Planning and Evaluation
(RICE).
o External
Link in with clinical engagement groups with Trusts and other
groups to contribute to pathway redesign. Also develop effective
linkages with Trust Heads of Pharmacy to facilitate better coordination of information flows between primary and secondary
care which would support, for example, improved medicines
reconciliation and thereby reduce risk of readmission and
improve patient flow.
Outcome: establish intersectoral discussions between clinicians
and managers to agree local implementation of commissioning
directions.
Medicines Management
o Identify and implement improvements for medicines
management across primary care to include extension of
prescription interventions; development of medication review to
respond to care pathway redesign; support the development of
targeted non-medical prescribing in line with strategic direction
o
Identify and address compliance support arrangements in line
with Board direction providing support to compliance support
pilots and roll-out e.g. through the development of training
arrangements for domiciliary care as opposed to provision of
MDS; educate/redirect patients/carers regarding compliance
support measures.
Outcome: Reduction in multiple dispensing; improved
compliance support arrangements; improved utilisation of
medicines with better outcomes for patients; development of
Medicines review services; reduction in costs and waste of
medicines.
Medicines Governance
o
Support HSCB in ensuring that patient safety and good
governance arrangements underpin the delivery of all services,
o Work with HSCB staff and practitioners to encourage adverse
incident reporting and uptake of learning by practitioners.
Outcome: Increased reporting of adverse incidents and implementation
of safer medicines systems and practices thereby improving medicines
safety and reducing admissions.
Pharmaceutical Public Health
o Support delivery of local commissioning of enhanced
pharmaceutical services which would include support for needs
assessment; consideration of service delivery; and performance
management
Outcome: pharmaceutical health improvement activities
strategically aligned and delivering against Joint Commissioning
Plan.
Prescribing
o Contribute to the review medicines management activity
(including prescribing) across ICPs to support the delivery of
pharmaceutical efficiency programmes.
Outcome: Contribute to delivery of agreed efficiency targets in
13/14 and maintain existing efficiencies from previous activity.
Working arrangements
1 Pharmacy Clinical Lead per ICP. Sessional, ‘as and when required’ until 31
March 2016 in the first instance, to max of 0.1wte (equivalent to 4 sessions
/month)
Remuneration
Equivalent to AfC mid-point Band 8d/4 hour session